Coherus BioSciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Coherus BioSciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| current account reveivables | 260,522,000 | 216,511,000 | 141,308,000 | 101,458,000 | 109,964,000 | 91,186,000 | 115,711,000 | 117,039,000 | 123,022,000 | 136,346,000 | 141,825,000 | 140,410,000 | 157,046,000 | 160,707,000 | 172,486,000 | 167,450,000 | 141,992,000 | 89,646,000 | 77,385,000 | 46,476,000 |
| current account payables | 35,219,000 | 37,092,000 | 29,278,000 | 23,231,000 | 11,526,000 | 9,917,000 | 17,486,000 | 21,092,000 | 16,159,000 | 45,707,000 | 14,568,000 | 15,482,000 | 15,201,000 | 11,990,000 | 21,179,000 | 20,485,000 | 25,985,000 | 13,709,000 | 19,273,000 | 11,173,000 |
We provide you with 20 years of balance sheets for Coherus BioSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Coherus BioSciences. Explore the full financial landscape of Coherus BioSciences stock with our expertly curated balance sheets.
The information provided in this report about Coherus BioSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.